Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown Origin

N/ACompletedNCT03466814

Bristol-Myers Squibb82 enrolled

Overview

Observational study of abatacept in the treatment of JIA in Japan.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Undifferentiated Arthritis

Interventions

Non-InterventionalOTHER

Non-Interventional

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * All JIA participants who initiate treatment with Orencia in accordance with the prescribing information Exclusion Criteria: * Participants receiving Orencia for an off-label indication Other protocol defined inclusion/exclusion criteria could apply

Locations (1)

Local Institution

Shinjuku-ku, Tokyo, Japan

Outcomes

Primary Outcomes

Number of adverse events

Time frame: 1 year

Secondary Outcomes

Safety measured by number of participants who receive at least 1 dose of Orencia

Time frame: 1 year

Efficacy measured by number of participants who receive at least 1 dose of Orencia

Time frame: 1 Year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.